迈瑞医疗：董事长李西廷增持15.23万股，后续拟继续增持

Core Viewpoint - The chairman of Mindray Bio-Medical Electronics Co., Ltd., Li Xiting, has increased his shareholding in the company, demonstrating confidence in its intrinsic value and future development [2] Group 1: Shareholding Increase - Li Xiting has purchased 152,340 shares at an average price of 196.862 RMB per share, totaling approximately 29.99 million RMB [2] - He plans to continue increasing his shareholding by an additional 200 million RMB over the next six months [2] Group 2: Company Overview - Mindray was established on January 25, 1999, with a registered capital of 12,124.41394 million RMB, focusing on the research, manufacturing, marketing, and service of medical devices [2] - The company has 21,667 employees and is controlled by Li Xiting and Xu Hang [3] Group 3: Financial Performance - The company's revenue for 2022, 2023, 2024, and the first three quarters of 2025 were 30.366 billion RMB, 34.932 billion RMB, 36.726 billion RMB, and 25.834 billion RMB, reflecting year-on-year growth rates of 20.17%, 15.04%, 5.14%, and a decline of 12.38% respectively [3] - The net profit attributable to shareholders for the same periods was 9.607 billion RMB, 11.582 billion RMB, 11.668 billion RMB, and 7.570 billion RMB, with year-on-year growth rates of 20.07%, 20.56%, 0.74%, and a decline of 28.83% respectively [3] - The company's debt-to-asset ratios were 31.55%, 30.44%, 28.04%, and 25.34% during the same periods [3]